§08
CLINICAL & GENOMIC PROTOCOLS DATABASE.
VALIDATED GENOMIC SCREENINGS // LAB CONTAINMENT // CLINICAL OUTBREAK RESPONSE PROTOCOLS
Live Surveillance Matrix:
... FACILITIES (Healthsites.io)
GENESTACK-EVD-01CLINICAL
Acute EVD Hemorrhagic Salvage & Monoclonal Infusion ProtocolSource: WHO / Africa CDC Clinical Management GuidelinesINSPECTINGGENESTACK-GEN-02GENOMIC
RT-PCR Genomic Identification & GP-Segment ScreeningSource: GISAID / WHO Laboratory Network GuidelinesGENESTACK-BSL-03CONTAINMENT
Biosafety Level 4 (BSL-4) Isolation & Ring VaccinationSource: MSF / WHO Field Operations ManualGENESTACK-EVD-01 · APPROVED INSTITUTIONAL PLAYBOOKAcute EVD Hemorrhagic Salvage & Monoclonal Infusion Protocol
Compliance:0%
Target Molecular PathwayEBOV Glycoprotein (GP) receptor binding domain
Clinical Biomarkers Tracked
Hematocrit < 35%Serum Creatinine > 2.0 mg/dLALT/AST > 3x NormalViral Load (Log10) > 6
Authoritative Guideline Reference
WHO / Africa CDC Clinical Management Guidelines
Facility & Gear Prerequisites
Peripheral/Central IV accessInfusion pumpsContinuous cardiac and SpO2 monitoringPoint-of-care biochemistry analyzer
Phase I: Aggressive Fluid Resuscitation & Electrolyte Management
Initiate rapid intravenous volume replacement with balanced crystalloids to counteract hypovolemic shock from GI losses.
Monitor potassium and sodium levels hourly; implement aggressive supplementation for hypokalemia to prevent cardiac arrhythmia.
Ensure secondary screening for malaria and typhoid fever to exclude co-infection in febrile patients.
Phase II: Targeted Monoclonal Antibody Administration
Administer monoclonal antibody therapy (mAb114 / Ebanga or REGN-EB3 / Inmazeb) immediately upon diagnostic confirmation.
Infuse Ebanga at a single dose of 50 mg/kg over 60 minutes, monitoring for infusion-related reactions (fever, chills).
For REGN-EB3, administer a single infusion of 150 mg/kg; maintain high-vibrancy surveillance for 4 hours post-infusion.